black box warning for glp 1 agonists Gastrointestinal Safety Assessment of GLP-1 Receptor in the US: A Real-World Adverse Events Analysis from the FAERS Database Diabetes advocacy group discourages

black box warning for glp 1 agonists Gastrointestinal Safety Assessment of GLP-1 Receptor in the US: A Real-World Adverse Events Analysis from the FAERS Database Diabetes advocacy group discourages

Diabetes advocacy group discourages use of compounded GLP-1 drugs | BioPharma Dive

Taken together, these efficacy and safety observations suggest that, for older patients without CV disease with T2DM who are not at A1C target despite metformin monotherapy, it is reasonable to preferentially recommend a DPP-4 inhibitor rather than an SGLT2 inhibitor as add-on therapy

The relevance to human therapy remains unclear (Nolte Kennedy & Masharani, 2015)